-
The overall confirmed cases on the Chinese mainland had reached 68,500 by the end of February 15. A total of 1,665 people have died of COVID-19, and altogether 9,419 people have been discharged from hospital after recovery.
-
The growth rate of China's daily new confirmed cases of COVID-19 outside Hubei has been dropping for 12 consecutive days.
-
Several antiviral drugs have been applied in clinical trials against COVID-19, and some have shown relatively good clinical efficacy.
-
As of Saturday midnight, Chongqing had reported a total of 544 confirmed cases, with 355 currently hospitalized (33 severe cases and 18 critical cases), five deaths, and 184 discharged patients.
- For all suspected cases, fever patients, and close contacts in Chongqing, full coverage of nucleic acid testing has been achieved.
The ninth Chongqing municipal medical team of 102 members to assist Hubei Province departed at Jiangbei International Airport on the evening of February 25. (Photo by Gan Xiayi)
Chongqing - As of 24:00 local time on February 15, Chongqing had reported a total of 544 confirmed cases infected by the coronavirus disease that was discovered in 2019 (COVID-19), according to the Chongqing Municipal Health Commission Sunday. There are 355 currently hospitalized confirmed cases (33 in severe condition and 18 in critical condition), five deaths, and 184 discharged patients after recovery.
A total of 21,589 people who had close contacts with COVID-19 patients have been traced, 16,708 people have been released from medical observation, and 4,881 people are under medical observation.
Chongqing dispatched its ninth municipal medical team of 102 members to assist Hubei Province on Saturday evening.
Full coverage of nucleic acid testing for key groups
According to Saturday's press conference on epidemic prevention and control, full coverage of nucleic acid testing has been achieved for all suspected cases, fever patients and close contacts. From February 12 to February 14, Chongqing had conducted a total of 14,394 nucleic acid tests. All confirmed and suspected cases have been taking treatment in designated hospitals, and all the infected without symptoms have been isolated concentrated in relevant hospitals.
According to the analysis of relevant data from February 6 to February 12, about 70% of the newly confirmed cases came from close contacts, indicating that strengthening the management of close contacts is very important for epidemic prevention and control.
In addition, employees returning to work shall stay in the factory and not leave their working place, dormitory, or designated area within 14 days. As of February 14, Chongqing had set up altogether 294 centralized isolation points with a total of 13,459 rooms. About 93% of close contacts still under medical observation take centralized isolation, and the rest for home-based quarantine.
Online administrative services
At present, a total of municipal-level government service departments and administrative services centers in all districts and counties across Chongqing have launched comprehensive online administrative services. From February 3 till now, the public has used the online platform named Yukuaiban to handle more than 20,000 items and inquire more than 100,000 times.
Moreover, the proportion of services completed online has reached 99.7%.
The overall confirmed cases on the Chinese mainland had reached 68,500 by the end of Saturday, and 1,665 people had died of the disease, according to the National Health Commission (NHC) Saturday. A total of 9,419 people had been discharged from the hospital after recovery. By the end of Saturday, 56 confirmed cases, including one death had been reported in the Hong Kong Special Administrative Region (SAR), 10 confirmed cases in the Macao SAR, and 18 in Taiwan. One patient in Hong Kong, three in Macao, and two in Taiwan have been discharged from hospital after recovery.
China's daily new confirmed cases of COVID-19 outside Hubei, the epicenter province in the outbreak, have been dropping for 12 consecutive days, according to the NHC Sunday.
Xinhua reported that several antiviral drugs had been applied in clinical trials against the novel coronavirus disease (COVID-19), and some have shown relatively good clinical efficacy, according to an official Saturday. Chinese researchers have narrowed down their focus to a few existing drugs, including Chloroquine Phosphate, Favipiravir, and Remdesivir, after multiple rounds of screening, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference on the new virus.